Associated tags: RWE, EEG, Algorithm, Machine learning, Patient, Biosignal, Brain, Sleep, Medical imaging, Pharmaceutical industry, Clinical trial, Research, Disorder, Beacon, DSM-IV codes, PSG, Arnal, Actigraphy, Drug development, Hypersomnia, Narcolepsy, Schizophrenia, Insomnia, Quality of life
Locations: MASSACHUSETTS
Retrieved on:
Thursday, February 1, 2024
Sleep,
Intelligence,
Molecular biology,
Software,
Growth,
MD,
Boston Consulting Group,
NIH,
Therapy,
Neuroscience,
Machine learning,
Patient,
Biological engineering,
Biosignal,
Disease,
Brain,
Partner,
Medicine,
NSF,
Medical device,
EEG,
Doctor of Philosophy,
Princeton University,
BCG,
University,
Health BOSTON, Feb. 1, 2024 /PRNewswire/ -- Beacon Biosignals, a leading computational neurodiagnostics and EEG analytics company, has appointed David Matthews, PhD, as Chief Business Officer to oversee commercial and strategic activities.
Key Points:
- Beacon Biosignals partners with top biopharma companies to better understand brain health using clinical-grade EEG and AI-powered analysis.
- The company's Dreem 3S wearable medical device enables validated sleep endpoints at-home and unlocks a scale of brain activity data never before available.
- Dr. Matthews will draw on his deep expertise in healthcare strategy, commercial development, and computational neuroscience to create new partnerships, expand relationships, and drive continued innovation for Beacon Biosignals through the company's next phase of growth.
- "We are thrilled to welcome David to our leadership team," said Jacob Donoghue, MD PhD, CEO of Beacon Biosignals.
Retrieved on:
Thursday, September 14, 2023
PSG,
AASM,
Krystal,
Classification,
Neurodegenerative disease,
Sleep,
Clinical trial,
Guilloché,
American Academy,
Atopic dermatitis,
Brain,
Research,
Disorder,
Development,
Literature,
Sleep disorder,
Electrode,
American Academy of Sleep Medicine,
DSM-IV codes,
Patient,
Machine learning,
EEG,
Algorithm,
Diagnosis,
Hospital,
FDA,
Massachusetts General Hospital,
Chronic pain,
Psychiatry,
Beacon,
Neurology,
Medical imaging,
Pharmaceutical industry BOSTON, Sept. 14, 2023 /PRNewswire/ -- Beacon Biosignals is thrilled to announce the milestone achievement of FDA 510(k) Clearance for the Dreem 3S, an advanced wearable headband with integrated machine learning algorithms to capture electroencephalogram (EEG) data from the brain to monitor sleep architecture and aid in the diagnosis of disturbed sleep. FDA Clearance marks it as equivalent to in-lab polysomnography for the assessment of sleep staging. The easy-to-use device makes it simple for patients to participate in clinically-validated, EEG-based sleep monitoring at home, unlocking new insights into sleep physiology. Beacon Biosignals, a health technology company whose work focuses on accelerating the development of treatments for neurological, psychiatric, and sleep disorders, acquired the Research and Development business of Dreem in July 2023. The Dreem 3S provides the company yet another asset to provide rich datasets that deepen the understanding of brain activity during sleep.
Key Points:
- FDA Clearance marks it as equivalent to in-lab polysomnography for the assessment of sleep staging.
- The easy-to-use device makes it simple for patients to participate in clinically-validated, EEG-based sleep monitoring at home, unlocking new insights into sleep physiology.
- Beacon Biosignals, a health technology company whose work focuses on accelerating the development of treatments for neurological, psychiatric, and sleep disorders, acquired the Research and Development business of Dreem in July 2023.
- The Dreem 3S provides the company yet another asset to provide rich datasets that deepen the understanding of brain activity during sleep.
DSM-IV codes,
Actigraphy,
Drug development,
Sleep,
Hypersomnia,
Arnal,
Schizophrenia,
Clinical trial,
Insomnia,
Quality of life,
Narcolepsy,
Research,
Brain,
Biomarker,
Disorder,
Science,
Neuropsychiatric Disease and Treatment,
Acquisition,
MD,
Machine learning,
EEG,
Beacon,
Alzheimer's disease,
Medical device,
Pharmaceutical industry,
Medical imaging,
Bad Dreems Dreem, a market leader in developing clinically-validated sleep monitoring devices, is poised to markedly enhance Beacon's capabilities in data acquisition and clinical trial operations, creating substantial value for Beacon's biopharma partners.
Key Points:
- Dreem, a market leader in developing clinically-validated sleep monitoring devices, is poised to markedly enhance Beacon's capabilities in data acquisition and clinical trial operations, creating substantial value for Beacon's biopharma partners.
- As part of this acquisition, Beacon Biosignals secured an undisclosed financing round with participation from its syndicate of Series A investors, led by General Catalyst.
- At-home, longitudinal monitoring is positioned to progress the underlying science of sleep physiology beyond what is possible with limited assessments in an unnatural sleep lab setting.
- Prominent sleep expert and Beacon Biosignals Scientific Advisory Board member, Dr. Andrew Krystal, MD, added, "Sleep plays a crucial role in neuropsychiatric diseases, and monitoring it in realistic, at-home settings is essential for understanding the full impact on patients.
